Fragile X Syndrome Market to Grow at a Substantial Growth Rate During the Forecast Period 2032 - Estimates DelveInsight | Key Companies - Zynerba, Novartis, Roche, Arcturus, Tetra Therapeutics, Autifony, Prilenia, and Others

DelveInsight's "Fragile X Syndrome (FXS) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Fragile X Syndrome Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Fragile X Syndrome market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Fragile X Syndrome (FXS): An Overview

Fragile X Syndrome (FXS) is a genetic disorder. FXS is caused by changes in a gene that scientists called the fragile X mental retardation 1 (FMR1) gene when it was first discovered. The FMR1 gene usually makes a protein called fragile X mental retardation protein (FMRP). People who have FXS do not make this protein. People who have other fragile X-associated disorders have changes in their FMR1 gene but usually make some of the protein.

Fragile X Syndrome (FXS) Market Key Facts

As per DelveInsight, the Fragile X Syndrome Market Size was found to be USD 35 Million in 2020, the market is expected to increase during the forecast period.

As of now, there is no cure for FXS. However, pharma and biotech companies are actively working to develop new therapies for the treatment of Fragile X Syndrome.

The total Fragile X Syndrome diagnosed prevalent population in the 7MM was estimated to be around 120,177 in 2020.

Among the 7MM, the most prevalent cases of Fragile X Syndrome (FXS) were recorded in the United States.

Among the European 5 countries, Germany had the highest prevalent population of Fragile X Syndrome (FXS), followed by France and the UK. On the other hand, Spain had the lowest prevalent population of Fragile X Syndrome (FXS).

FXS affects both males and females. However, females often have milder symptoms than males.

Find a sample copy of the Fragile X Syndrome Market report at:
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Fragile X Syndrome (FXS) Market

As per DelveInsight, the Fragile X Syndrome Market is expected to grow in the coming years owing to the expected entry of emerging therapies with novel targets and pricing. Furthermore, the impending products such as Zygel, Acamprosate, BPN14770, OV101, and Trofinetide are anticipated to expand the market with more penetration in the 7MM markets.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Fragile X Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Fragile X Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request a sample and discover more about the report offerings @
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Fragile X Syndrome (FXS) Epidemiology

The epidemiology section covers detailed insights into the historical and current Fragile X Syndrome patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Fragile X Syndrome (FXS) Epidemiology Segmentation
Total Diagnosed Prevalent Cases of Fragile X Syndrome
Gender-specific Diagnosed Prevalent Cases of Fragile X Syndrome
Age-specific Diagnosed Prevalent Cases of Fragile X Syndrome

Explore more about the Fragile X Syndrome Epidemiology @
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Fragile X Syndrome (FXS) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fragile X Syndrome market or expected to get launched in the market during the study period. The analysis covers Fragile X Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Fragile X Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for a sample report to understand more about the Fragile X Syndrome pipeline development activities @
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Fragile X Syndrome (FXS) Therapeutics Assessment
Currently, there is no cure for FXS. However, several options are available in the market that can help people learn important skills. Additionally, therapies can also help to control some issues, such as behaviour problems.

Globally, approx. 35+ key companies which are developing the Fragile X Syndrome Therapies The companies which have their Fragile X Syndrome drug candidates in the most advanced stage, i.e. phase II/III include Zynerba Pharmaceuticals and others

Some of the leading companies in the Fragile X Syndrome Market include Zynerba Pharmaceuticals, Tetra Therapeutics, Confluence Pharmaceuticals, Autifony Therapeutics, Prilenia Therapeutics, Ovid Therapeutics, Neuren Pharmaceuticals, Arcturus Therapeutics/Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Hoffmann-La Roche, and Others.

The key therapies in the Fragile X Syndrome Therapeutics Market include Zygel (Cannabidiol/ZYN002), Acamprosate, BPN14770, OV101 (gaboxadol), AUT00206, Pridopidine, Trofinetide (NNZ-2566), and many more.

Learn more about the emerging therapies & key companies in the Fragile X Syndrome Therapeutics Market @
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Fragile X Syndrome Report Key Insights

1. Fragile X Syndrome Patient Population
2. Fragile X Syndrome Market Size and Trends
3. Key Cross Competition in the Fragile X Syndrome Market
4. Fragile X Syndrome Market Dynamics (Key Drivers and Barriers)
5. Fragile X Syndrome Market Opportunities
6. Fragile X Syndrome Therapeutic Approaches
7. Fragile X Syndrome Pipeline Analysis
8. Fragile X Syndrome Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Fragile X Syndrome Market

Table of Content (TOC)

1. Key Insights
2. Executive Summary
3. Fragile X Syndrome Competitive Intelligence Analysis
4. Fragile X Syndrome Market Overview at a Glance
5. Fragile X Syndrome Disease Background and Overview
6. Fragile X Syndrome Patient Journey
7. Fragile X Syndrome Epidemiology and Patient Population
8. Fragile X Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Fragile X Syndrome Unmet Needs
10. Key Endpoints of Fragile X Syndrome Treatment
11. Fragile X Syndrome Marketed Products
12. Fragile X Syndrome Emerging Therapies
13. Fragile X Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Fragile X Syndrome Market Outlook (7 major markets)
16. Fragile X Syndrome Access and Reimbursement Overview
17. KOL Views on the Fragile X Syndrome Market.
18. Fragile X Syndrome Market Drivers
19. Fragile X Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Fragile X Syndrome Market report here:
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.